GrafixPL PRIME Evaluation Case Study

University of Texas Southwestern Medical Center40 enrolled

Overview

The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40) that receive optimal treatment including serial wound debridement and off-loading with total contact casts or a boot and GrafixPL PRIME. In addition, the investigators will collect data on other potential confounding factors that could affect healing such as medications, tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity. Wound healing, including wound size and adverse events will be evaluated. The objective of this study is to understand the use of this product to evaluate wound healing in 40 patients.

Screening and Enrollment: * Review and sign the Informed Consent and HIPAA Authorization * Review the inclusion and exclusion criteria If the subject qualifies for the study, they will participate in the following procedures (weekly visits, +/-4 days): Visit 0: * Demographics (such as age, gender, race or ethnicity) * Medical/Surgical and Social History, Current Antibiotics. * Laboratory Results * Vascular - ABI * Neurological evaluation - Monofilament and VPT * Vitals - Sitting blood pressure and Pulse rate, Height/Weight, and BMI * Wound debridement * eKare - Wound imaging measurement * Application of GrafixPL PRIME * Current Antibiotics * Offloading * Adverse Events * Source documentation Visits 1 - 11: * Wound debridement * eKare - Wound imaging measurement * Application of GrafixPL PRIME * Current Antibiotics * Offloading * Adverse Events * Source documentation Visit 12/End of Study (EOS) Visit: * Wound debridement * eKare - Wound imaging measurement * Current Antibiotics * Offloading * Adverse Events * Source documentation (End of Study will occur on the date the subject is healed)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Foot Ulcer

Interventions

GrafixPL PRIMEBIOLOGICAL

GrafixPL PRIME

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Able to provide informed consent * 18-90 years of age * Chronic foot ulceration below the ankle - persistent for 30 days or longer * Ankle Brachial Index (ABI) \>0.5 (Bedside ABI is acceptable for screening purposes as the formal imaging ABI may not be resulted prior to surgery) Exclusion Criteria: * Unable to provide informed consent * \<18 or \>90 years of age * History of poor compliance with follow-up visits * Gangrene * Untreated Osteomyelitis * Widespread malignancy * Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines * Currently Pregnant or planning pregnancy during the course of intended participation in the study * Is nursing or actively lactating

Locations (1)

UT Southwestern Medical Center at Dallas

Dallas, Texas, United States

Outcomes

Primary Outcomes

Number of Participants With Complete Closure of the Index Ulcer

Complete closure of the index ulcer, defined as 100% re-epithelialization as determined by the Investigator by week 12 or the End of Treatment Visit.

Time frame: 12 weeks

Secondary Outcomes

Time to Closure

Time frame: 12 weeks

Total Adverse Events

There was no control arm in this study - everyone enrolled received treatment. Analysis of these data was separated into two groups - "closed wounds" and "not closed wounds." Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.